LXEO — Lexeo Therapeutics, Inc. Stock Price, Chart & AI Report

Positive Jan 12, 2026 • 12:00 UTC GlobeNewswire Inc. • Na

Lexeo Therapeutics Announces Positive Interim Phase I/II Data for LX2020 for the Treatment of PKP2-Associated Arrhythmogenic Cardiomyopathy

Lexeo Therapeutics reported positive interim Phase I/II data for LX2020, an AAV-based gene therapy for PKP2-associated arrhythmogenic cardiomyopathy. The therapy demonstrated good tolerability across 10 participants, with 93-162% increases in PKP2 protein expression and stabilization or improvement in arrhythmia burden in the majority of participants. The company plans to complete 12-month data collection by Q4 2026 and engage with regulators in 2026.

LXEO gene therapy AAV arrhythmogenic cardiomyopathy PKP2 Phase I/II trial cardiac disease protein expression

Sentiment note

The company announced positive interim clinical trial data showing good safety profile, robust transduction, meaningful increases in PKP2 protein expression (93-162%), and clinically meaningful improvement or stabilization in arrhythmia burden across the majority of participants. No serious safety concerns were reported, and the therapy addresses an unmet medical need in a rare disease affecting approximately 60,000 people in the US.

Positive Jan 8, 2026 • 12:00 UTC GlobeNewswire Inc. • Na

Lexeo Therapeutics Announces Research Collaboration to Explore Targeted Cardiac Delivery of AAV Gene Therapy

Lexeo Therapeutics announced a research collaboration with Johnson & Johnson to investigate localized cardiac delivery of AAV gene therapy using Impella heart pump technology. The partnership aims to improve the efficacy and safety of gene therapy for genetically mediated cardiovascular diseases by concentrating viral delivery to the heart while reducing required AAV doses.

LXEO JNJ AAV gene therapy cardiac delivery Impella heart pumps cardiovascular diseases genetic medicine research collaboration

Sentiment note

The company announced a strategic collaboration with a major pharmaceutical leader (Johnson & Johnson) to advance its cardiac gene therapy platform. This partnership validates Lexeo's technology, provides access to complementary expertise and established cardiovascular technologies, and accelerates development of preclinical cardiac targets, which are positive indicators for the company's pipeline and market potential.

Positive Oct 17, 2025 • 03:29 UTC GlobeNewswire Inc. • Lexeo Therapeutics

Lexeo Therapeutics Announces Pricing of Public Offering and Concurrent Private Placement

Lexeo Therapeutics has priced a public offering and private placement, raising approximately $135 million by selling 15,625,000 shares at $8.00 per share and pre-funded warrants to Balyasny Asset Management.

LXEO public offering private placement genetic medicine cardiovascular diseases

Sentiment note

Successfully raised $135 million through public offering and private placement, indicating investor confidence in the company's genetic medicine approach for cardiovascular diseases

Positive Oct 7, 2025 • 10:00 UTC GlobeNewswire Inc. • Lexeo Therapeutics

Lexeo Therapeutics Announces Progress in FDA Discussions for Accelerated Approval Pathway and Positive Interim Clinical Data for LX2006 in Friedreich Ataxia Cardiomyopathy

Lexeo Therapeutics reports positive interim clinical data for LX2006, a gene therapy for Friedreich Ataxia cardiomyopathy, with FDA openness to an accelerated approval pathway and promising results showing cardiac and neurologic improvements.

LXEO gene therapy Friedreich Ataxia cardiomyopathy FDA approval clinical trials

Sentiment note

Company demonstrated promising clinical trial results, positive FDA engagement, potential for accelerated approval pathway, and no significant safety concerns in interim data

Positive Apr 7, 2025 • 10:00 UTC GlobeNewswire Inc. • Lexeo Therapeutics

Lexeo Therapeutics Announces Positive Interim Phase 1/2 Data for LX2006 in Friedreich Ataxia Cardiomyopathy Supporting Advancement to Registrational Study

Lexeo Therapeutics announces positive interim data for its gene therapy candidate LX2006 in treating Friedreich ataxia cardiomyopathy, with participants showing clinically significant improvements in cardiac biomarkers and increased frataxin expression. The company plans to initiate a registrational study by early 2026.

LXEO Lexeo Therapeutics LX2006 Friedreich ataxia cardiomyopathy gene therapy

Sentiment note

The article reports positive interim data for Lexeo's gene therapy candidate LX2006, which showed clinically significant improvements in cardiac biomarkers and increased frataxin expression in participants with Friedreich ataxia cardiomyopathy. The company plans to advance the program to a registrational study, indicating confidence in the therapy's potential.

Positive Mar 26, 2025 • 16:31 UTC Investing.com • Marketbeat.Com

2 Stocks Riding the Biotech Surge With Major Catalysts Ahead

The biotechnology sector has experienced significant volatility, with Tonix Pharmaceuticals and Lexeo Therapeutics seeing major stock price surges. These surges were driven by positive regulatory updates and financial results, respectively, indicating potential long-term value for these companies.

TNXP LXEO biotechnology Tonix Pharmaceuticals Lexeo Therapeutics regulatory updates financial results

Sentiment note

Lexeo Therapeutics' stock price increased by 50.92% following the release of its strong financial results, with cash reserves expected to last into 2027. The company is also making progress in its gene therapy pipeline, including positive regulatory feedback and promising early clinical data, suggesting potential long-term value.

Positive Aug 12, 2024 • 11:00 UTC GlobeNewswire Inc. • N/A

Lexeo Therapeutics Reports Second Quarter 2024 Financial Results and Operational Highlights

Lexeo Therapeutics reported positive interim data from Phase 1/2 studies in Friedreich ataxia cardiomyopathy, showing LX2006 was well-tolerated and demonstrated evidence of sustained treatment effect. The company also initiated formal engagements with the FDA on surrogate endpoints for a registrational study and expects to provide an update by the end of 2024.

LXEO Lexeo Therapeutics Friedreich ataxia LX2006 FDA clinical trials

Sentiment note

The company reported positive interim data from its Phase 1/2 studies in Friedreich ataxia cardiomyopathy, showing its lead candidate LX2006 was well-tolerated and demonstrated evidence of sustained treatment effect. The company also initiated formal engagements with the FDA on surrogate endpoints for a registrational study, indicating progress in its development efforts.

Positive Jul 15, 2024 • 10:02 UTC GlobeNewswire Inc. • N/A

Lexeo Therapeutics Announces Positive Interim Phase 1/2 - GlobeNewswire

Lexeo Therapeutics announced positive interim data from its Phase 1/2 clinical trial of LX2006, a gene therapy candidate for the treatment of Friedreich ataxia cardiomyopathy. The data showed clinically meaningful improvements in cardiac biomarkers and increased frataxin protein expression in participants.

LXEO Lexeo Therapeutics LX2006 Friedreich ataxia cardiomyopathy gene therapy

Sentiment note

The article reports positive interim data from Lexeo's clinical trial, indicating the potential of their gene therapy candidate LX2006 to treat Friedreich ataxia cardiomyopathy.

Unknown May 14, 2024 • 16:00 UTC Zacks Investment Research • Zacks Equity Research

What Makes Lexeo Therapeutics, Inc. (LXEO) a New Buy Stock

Lexeo Therapeutics, Inc. (LXEO) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

LXEO

Unknown May 14, 2024 • 13:55 UTC Zacks Investment Research • Zacks Equity Research

Wall Street Analysts Think Lexeo Therapeutics, Inc. (LXEO) Could Surge 57.82%: Read This Before Placing a Bet

The mean of analysts' price targets for Lexeo Therapeutics, Inc. (LXEO) points to a 57.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

LXEO

Unknown May 9, 2024 • 11:00 UTC GlobeNewswire Inc. • Lexeo Therapeutics

Lexeo Therapeutics Reports First Quarter 2024 Financial Results and Operational Highlights

LXEO Earnings Releases and Operating Results

Unknown May 7, 2024 • 11:30 UTC GlobeNewswire Inc. • Lexeo Therapeutics

Lexeo Therapeutics to Participate in Upcoming Investor Conferences

LXEO Calendar of Events Conference Calls/ Webcasts Clinical Study